Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2026-01-17
Target enrollment:
Participant gender:
Summary
This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3
consecutive days, and 28 days as a cycle. Tumor imaging evaluation was performed every 8±1
weeks from the first dose of C1D1 until an event that met the criteria for treatment
discontinuation occurred.